Proactive Investors - Run By Investors For Investors

Motus GI Holdings Inc aims to raise $20 million as it bolsters its Pure-Vu colonoscopy system

The firm is boosting commercialization, as well as research and development of its Pure-Vu system, which is aimed at improving clinical outcomes and enhancing the cost-efficiency of colonoscopy
Motus GI is focused on improving clinical outcomes and enhancing the cost-efficiency of colonoscopy

Motus GI Holdings Inc (NASDAQ:MOTS) said Thursday it is planning to raise up to $20 million in a public offering with to bolster commercialization and research and development activities for its Pure-Vu system, which is aimed at improving clinical outcomes and enhancing the cost-efficiency of colonoscopy.

The Fort Lauderdale, Florida-based Motus GI flagship Pure-Vu System is a medical device cleared by the Food and Drug Administration designed to reduce costs by facilitating the cleaning of a poorly prepped colon during colonoscopy procedures. It provides safe and rapid bowel cleansing. 

Funds raised from the underwritten public offering will go towards commercialization activities for the Pure-Vu System, as well as to continue research and development activities, including clinical and regulatory development. 

READ: Motus GI says sales force expanded before launch of Pure-Vu colonoscopy system

The facts are simple: inadequate bowel preparation prior to colonoscopy affects a significant percentage of patients’ ability to receive a complete and high-quality exam. If not prepped properly, it can lead to delayed or cancelled procedures, which can increase costs for patients and providers. 

The firm said it will offer 6.67 million shares at a price of $3 per share, with gross proceeds expected at around $20 million, before deductions and commissions. 

The firm has subsidiaries in the US and Israel, and said it plans to use the remaining net proceeds for working capital and other general corporate purposes. The firm noted it may also use a portion of the proceeds to acquire additional technologies, assets or businesses, and other strategic investments.

Shares in Motus GI traded at $3.09 on Thursday afternoon. 

Contact Katie Lewis at [email protected]

View full MOTS profile View Profile

Motus GI Timeline

Related Articles

June 24 2019
Long-term fundamentals remain firmly in the seafood specialist's favour
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use